Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06840652 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption

Study acronym: BAWIC
StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 21, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study examines the safety and effectiveness of baclofen as a treatment for alcohol withdrawal in patients with chronic liver disease who continue drinking. It aims to evaluate baclofen's ability to promote alcohol abstinence or reduction while monitoring adverse effects. Secondary outcomes include liver function changes, hospital readmissions, and complications of cirrhosis. Alcohol consumption worsens liver disease prognosis, yet alcohol use disorder (AUD) often goes untreated. Baclofen, which is safe for patients with liver impairment, is recommended as a first-line treatment for AUD in chronic liver disease. This prospective study collects data from patients treated with baclofen at Parc Taulí Hospital, analyzing outcomes at three and six months to assess abstinence, alcohol reduction, and adverse effects.
Trial Details
NCT Number NCT06840652
Lead Sponsor Corporacion Parc Tauli
Conditions
(from sponsor)		 Alcoholic Cirrhosis, Alcohol Abstinence, Alcohol Withdrawal, Medication Toxicity, Medication Adherence
Related terms Alcohol Abstinence, Drug-Related Side Effects and Adverse Reactions, Liver Cirrhosis, Alcoholic, Medication Adherence
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov